RNA-sequence data of clinically never-metastatic primary small cell lung cancer cases and small cell lung cancer metastasis cases, FOXA2 knock-down and overexpression in cell lines
RNA-seq (gene expression) · human · 61 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Small cell lung cancerThis series is part of our curated briefing on it.
- Samples
- 61 samples: 11 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- FOXA2 promotes metastatic competence in small cell lung cancerNature communications · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE281525_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1184332 and SRA study SRP544319. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 37 samples read as cases, 9 as controls.
How we read this: 11 replicated groups read from 61 sample titles; they account for 61 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8622668 Never-met primary tumor, sample1 Never-met primary tumor…
- GSM8622669 Never-met primary tumor, sample2 Never-met primary tumor…
- GSM8622670 Never-met primary tumor, sample3 Never-met primary tumor…
- GSM8622671 Never-met primary tumor, sample4 Never-met primary tumor…
- GSM8622672 Never-met primary tumor, sample5 Never-met primary tumor…
- GSM8622673 Never-met primary tumor, sample6 Never-met primary tumor…
- GSM8622674 Never-met primary tumor, sample7 Never-met primary tumor…
- GSM8622675 Met-associated primary tumor , sample1 Met-associated primary …
- GSM8622676 Met-associated primary tumor , sample2 Met-associated primary …
- GSM8622677 Met-associated primary tumor , sample3 Met-associated primary …
- GSM8622678 Met-associated primary tumor , sample4 Met-associated primary …
- GSM8622679 Met-associated primary tumor , sample5 Met-associated primary …
- GSM8622680 Metastatsis, sample1 Metastatsis, sample
- GSM8622681 Metastatsis, sample2 Metastatsis, sample
- GSM8622682 Metastatsis, sample3 Metastatsis, sample
- GSM8622683 Metastatsis, sample4 Metastatsis, sample
- GSM8622684 Metastatsis, sample5 Metastatsis, sample
- GSM8622685 Metastatsis, sample6 Metastatsis, sample
- GSM8622686 Metastatsis, sample7 Metastatsis, sample
- GSM8622687 Metastatsis, sample8 Metastatsis, sample
- GSM8622688 Metastatsis, sample9 Metastatsis, sample
- GSM8622689 Metastatsis, sample10 Metastatsis, sample
- GSM8622690 Metastatsis, sample11 Metastatsis, sample
- GSM8622691 Metastatsis, sample12 Metastatsis, sample
- GSM8622692 Metastatsis, sample13 Metastatsis, sample
- GSM8622693 Metastatsis, sample14 Metastatsis, sample
- GSM8622694 Metastatsis, sample15 Metastatsis, sample
- GSM8622695 Metastatsis, sample16 Metastatsis, sample
- GSM8622696 Metastatsis, sample17 Metastatsis, sample
- GSM8622697 Metastatsis, sample18 Metastatsis, sample
- GSM8622698 Metastatsis, sample19 Metastatsis, sample
- GSM8622699 Metastatsis, sample20 Metastatsis, sample
- GSM8622700 Metastatsis, sample21 Metastatsis, sample
- GSM8622701 Metastatsis, sample22 Metastatsis, sample
- GSM8622702 Metastatsis, sample23 Metastatsis, sample
- GSM8622703 Metastatsis, sample24 Metastatsis, sample
- GSM8622704 Metastatsis, sample25 Metastatsis, sample
- GSM8622705 H1836, control sample1 H1836, control sample
- GSM8622706 H1836, control sample2 H1836, control sample
- GSM8622707 H1836, control sample3 H1836, control sample
+ 21 more — browse all 61 samples with per-sample file links →
- GSE259271 Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer (RNA-Seq) 3 samples same disease briefing · shares metastasis
- GSE259273 Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer 7 samples same disease briefing · shares metastasis
- GSE259272 Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer (ChIP-Seq) 4 samples same disease briefing · shares metastasis
- GSE272002 LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC 324 samples same disease briefing
- GSE208446 Small cell lung cancer responds to inhibition of Jumonji enzyme in vitro and in vivo 90 samples same disease briefing
- GSE255095 An in vivo screening platform using PDX models reveals KEAP1, USP22 and other drivers of chemoresistance in small cell lung cancer 67 samples same disease briefing
- GSE262597 EIF6 conditions drug-tolerant persister-like transdifferentiation in small cell lung carcinoma 56 samples same disease briefing
- GSE279100 Differential KEAP1/NRF2-mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy [seq] 50 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.